Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALDAS: Effect of imeglimin on muscle mass and quality in older patients with type 2 diabetes at risk for sarcopenia
jRCTs061250018Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Primary: Change in 5-times chair-stand test at 24 weeks. Started May 2025; status: recruiting.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs061250018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061250018.